- Home
- NAMS vs DAN Comparison
NAMS vs DAN Comparison
Compare NAMS & DAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NAMS | DAN |
|---|---|---|
| Founded | 2019 | 1904 |
| Country | Netherlands | United States |
| Employees | 100 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Auto Parts:O.E.M. |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.3B |
| IPO Year | N/A | 1998 |
Fundamental Metrics
Financial Performance| Metric | NAMS | DAN |
|---|---|---|
| Price | $28.50 | $36.00 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 5 |
| Target Price | ★ $46.75 | $40.60 |
| AVG Volume (30 Days) | 838.8K | ★ 844.4K |
| Earning Date | 05-06-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 1.34% |
| EPS Growth | N/A | ★ 264.10 |
| EPS | N/A | ★ 0.64 |
| Revenue | N/A | ★ $7,500,000,000.00 |
| Revenue This Year | $17.96 | $1.89 |
| Revenue Next Year | $540.65 | $4.59 |
| P/E Ratio | ★ N/A | $57.38 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $16.79 | $14.16 |
| 52 Week High | $42.00 | $39.56 |
Technical Indicators
Market Signals| Indicator | NAMS | DAN |
|---|---|---|
| Relative Strength Index (RSI) | 36.61 | 50.41 |
| Support Level | $23.48 | $34.66 |
| Resistance Level | $37.25 | $36.28 |
| Average True Range (ATR) | 1.69 | 1.34 |
| MACD | -0.61 | -0.26 |
| Stochastic Oscillator | 7.88 | 26.73 |
Price Performance
Historical ComparisonAbout NAMS NewAmsterdam Pharma Company N.V.
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.
About DAN Dana Incorporated
Dana Inc is engaged in the designing and manufacturing of efficient propulsion and energy-management solutions that power vehicles and machines in all mobility markets across the globe. The company has four operating segments: Light Vehicles, Power Technologies, Commercial Vehicle, and Off-Highway. The Light Vehicles segment generates the majority portion of revenue by providing products to support light vehicle OEMs. Its products are designed for light trucks, SUVs, CUVs, vans, and passenger cars.